Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-16, Stock:JNJ, The news for the past five days is as follows:
2018-04-09: NEWS1: Billionaire Ken Fisher’s Favorite Dividend Stocks.NEWS2: How Johnson & Johnson Stock Performed in 1Q18.NEWS3: Glancy Prongay & Murray LLP Reminds Investors of the April 9, 2018 Deadline in the Class Action Lawsuit Against Johnson & Johnson.NEWS4: Pharma’s Latest: Mergers and Acquisitions in 1Q18.NEWS5: DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS6: DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ.NEWS7: 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain.
2018-04-10: NEWS1: FDA Approves First Contact Lens With Light-adaptive Technology.NEWS2: FDA Approves First Contact Lens With Light-adaptive Technology.NEWS3: Why J&J’s Fallen Stock Is Still Too Pricey.NEWS4: DGRO, JNJ, AAPL, MSFT: ETF Inflow Alert.NEWS5: DGRO, JNJ, AAPL, MSFT: ETF Inflow Alert.NEWS6: Google to power Georgia data center with solar energy.NEWS7: How Merck & Co. Stock Performed in 1Q18.NEWS8: Analyst Recommendations for Teva Pharmaceutical in April 2018.NEWS9: Analyst Recommendations for Valeant Pharmaceuticals in April.NEWS10: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS11: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS12: Wired News – Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc.NEWS13: Novartis and Other Drug Stocks With FDA Catalysts in April.
2018-04-11: NEWS1: J&J, Imerys unit must pay $117 million in New Jersey asbestos cancer case.NEWS2: J&J, Imerys unit must pay $117 mln in N.J. asbestos cancer case.NEWS3: Novartis’s Valuation and Analysts’ Recommendations on April 11.NEWS4: Asbestos in Talc Products Verdict Means J&J, Imerys Owe Millions.NEWS5: J&J, Imerys must pay $80 mln punitive damages in case linking cancer to asbestos in talc.NEWS6: Novartis’s Stock Performance following the AveXis Agreement.NEWS7: Karyopharm's Myeloma Candidate Gets Fast Track Designation.NEWS8: Karyopharm's Myeloma Candidate Gets Fast Track Designation.NEWS9: Dow Analyst Moves: JNJ.NEWS10: Dow Analyst Moves: JNJ.NEWS11: 4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings.NEWS12: 4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings.NEWS13: Alkermes Has Some Decisions to Make.NEWS14: Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 12, 2018.NEWS15: Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 12, 2018.NEWS16: 4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings.NEWS17: How GlaxoSmithKline Stock Performed in 1Q18.NEWS18: [$$] Healthcare: Cancer breakthrough leads China’s biotech boom.
2018-04-12: NEWS1: U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report.NEWS2: Top ETF Picks for Your IRA.NEWS3: Top ETF Picks for Your IRA.NEWS4: Why Geron Corporation Stock Is on the Rise Today.NEWS5: Why Geron Corporation Stock Is on the Rise Today.NEWS6: Top ETF Picks for Your IRA.NEWS7: A Look at Johnson & Johnson’s Darzalex.NEWS8: Why Geron Corporation Stock Is on the Rise Today.NEWS9: Get a look at Johnson & Johnson&apos;s HQ expansion in Lake Nona (RENDERINGS).NEWS10: J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?.NEWS11: J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?.NEWS12: J&J (JNJ) to Begin Pharma Q1 Earnings: What&apos;s in Store?.NEWS13: Ad Prices On Fox's 'The Ingraham Angle' Fall In The Wake Of Advertiser Boycott.NEWS14: Ad Prices On Fox's The Ingraham Angle Fall In The Wake Of Advertiser Boycott.NEWS15: Ad Prices On Fox's "Ingraham Angle" Fall In The Wake Of Advertiser Boycott.
2018-04-13: NEWS1: Local experts talks artificial intelligence on the First Coast.NEWS2: Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?.NEWS3: Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?.NEWS4: Here's Why Geron Stock Surged More Than 90% in 6 Months.NEWS5: Here's Why Geron Stock Surged More Than 90% in 6 Months.NEWS6: Stocks Close Mostly Lower After Seeing Initial Strength - U.S. Commentary.NEWS7: Stocks Close Mostly Lower After Seeing Initial Strength - U.S. Commentary.NEWS8: Here&apos;s Why Geron Stock Surged More Than 90% in 6 Months.NEWS9: Is J&J&apos;s (JNJ) Pharma Segment Likely to Drive Q1 Earnings?.NEWS10: Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson.NEWS11: With A -92.14% Earnings Drop, Did Johnson & Johnson (NYSE:JNJ) Really Underperform?.NEWS12: Can Johnson & Johnson Get Its Mojo Back?.NEWS13: Can Johnson & Johnson Get Its Mojo Back?.NEWS14: Why Geron Corporation Stock Popped 84% in March.NEWS15: Why Geron Corporation Stock Popped 84% in March.NEWS16: Can Johnson & Johnson Get Its Mojo Back?.NEWS17: Modest Weakness Remains Visible On Wall Street - U.S. Commentary.NEWS18: Modest Weakness Remains Visible On Wall Street - U.S. Commentary.NEWS19: Why Geron Corporation Stock Popped 84% in March.NEWS20: Stocks Turn Lower After Initial Move To The Upside - U.S. Commentary.NEWS21: Stocks Turn Lower After Initial Move To The Upside - U.S. Commentary.NEWS22: Stocks May Open Higher On Upbeat Earnings News - U.S. Commentary.NEWS23: Stocks May Open Higher On Upbeat Earnings News - U.S. Commentary.

Answer: Rise